DolCas Biotech is a natural products ingredient firm, specializing in the commercial development and market positioning of clinically studied, patented brands. As an invested partner through the entire process, DolCas directs the evolution of science that supports these ingredients, the safety evaluations that bring assurance to the end-consumer and the marketing and service support that fuels innovation and growth for its customers. DolCas Biotech was established in 2007 as an extension of its founding corporation Orcas Naturals. With an already developed acumen in the area of generic powders and extracts trading, the pioneering vision for DolCas was a timely response to the then budding interest in branded nutraceuticals. Pivoting successfully would require a more attentive focus on customers, a more thorough understanding of science and an evolving sense of the prevailing trends of the industry - and DolCas dived in head-first. It expanded and enriched its teams, endeavored to spearhead scientific inquiry on its brands through internal investments and prioritized portfolio development and diversification by setting, versus following industry trends. DolCas expanded its scope, becoming vertically integrated with the establishment of its own manufacturing facilities in Bikaner, India – DolCas Botanosys, in 2017. With a bespoke portfolio of seven, novel, science-substantiated brands, DolCas Biotech is looking to expand its offering of patented, clinically-studied, health benefit ingredients over the next 5 years, both by partnership and internal ingenuity. Recently acknowledged by the globally recognized business and technology magazine The Silicon Review as one of 2020's '50 Most Innovative Companies to Watch', DolCas is excited to expound on its commitments to produce, procure and promote brands with the highest possible quality and safety standards and do our part in helping people transform their lives through health and wellness.